Key terms
About ALRN
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALRN news
Mar 29
8:12am ET
Aileron Therapeutics Announces CFO Transition and Appointment
Mar 12
8:11am ET
Aileron Therapeutics CEO Manuel Aivado steps down, Brian Windsor to succeed
Mar 01
4:24pm ET
Aileron Therapeutics: Board Shake-Up and Nasdaq Compliance Success
Feb 29
7:13am ET
Aileron Therapeutics’ Shareholders Approve Major Stock Proposals
Feb 13
7:12am ET
Aileron Therapeutics Grants COO Performance Bonus for 2023
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Jan 30
9:51am ET
Aileron Therapeutics trading resumes
Jan 30
9:46am ET
Aileron Therapeutics trading halted, volatility trading pause
Jan 29
4:11pm ET
Aileron Therapeutics files to sell 7.06M shares of common stock for holders
Jan 26
4:06am ET
Aileron Therapeutics Issues Update on Current Report 8-K
No recent press releases are available for ALRN
ALRN Financials
Key terms
Ad Feedback
ALRN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALRN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
